New nanocrystal drug aims to fight cancer wasting during chemoradiation

NCT ID NCT07338487

Recruiting now Symptom relief Sponsor: Second Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new, easier-to-absorb version of megestrol acetate (a drug that stimulates appetite) in 5 women with advanced cervical cancer who are undergoing chemoradiation. The goal is to see if it helps them maintain weight and improve nutrition during treatment. The study compares the drug plus standard therapy against standard therapy alone over 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nanocrystalline megestrol acetate oral suspension
What this could lead to: If it works, this could help patients with advanced cervical cancer maintain weight and appetite during chemoradiation, potentially improving treatment tolerance and quality of life.
What could go wrong: This is a very early phase 1 trial with only 5 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CACHEXIA LOCALLY ADVANCED CERVICAL CANCER

Contacts and locations

Locations

Xiangya Second Hospital of Central South University
RECRUITING

Changsha, Hunan, 410011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.